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Introduction
Hyperacusis is a clinical phenomenon that broadly encom-
passes various adverse reactions to sound. Determining the 
prevalence of hyperacusis was identified as a major research 
question in a 2018 review of gaps in knowledge regarding 
hyperacusis.1 The reported prevalence of hyperacusis in 
children and adolescents has ranged between 3.2% and 
17.1%.2 Tyler et al., in their review of the literature, defined 
four subtypes of hyperacusis that may occur singly or in 
combination. These are: “loudness hyperacusis,” where 
normal volume sounds are perceived as loud; “annoyance 
hyperacusis,” where sounds may cause mood disturbance; 
“fear hyperacusis,” where there are perseverative thoughts 
about loud sounds and consequent avoidant behavior; and 
“pain hyperacusis,” where there is a lowered threshold for 
sound-induced pain.3 Left untreated, hyperacusis has been 
shown to be associated with significant emotional and 
behavioral consequences.4,5
Given the variability in the presentations of hyperacusis, it 
is unsurprising that hyperacusis is also associated with many 
different disorders. Hyperacusis is a common feature of hear-
ing loss disorders, neurodevelopmental disorders, and vari-
ous psychiatric and chronic pain disorders such as Meniere’s 
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Abstract
Objectives: To evaluate the efficacy of a multi-modal migraine prophylaxis therapy for patients with hyperacusis.
Methods: In a prospective cohort, patients with hyperacusis were treated with a multi-modal step-wise migraine 
prophylactic regimen (nortriptyline, verapamil, topiramate, or a combination thereof) as well as lifestyle and dietary 
modifications. Pre- and post-treatment average loudness discomfort level (LDL), hyperacusis discomfort level measured by 
a visual analogue scale (VAS), and scores on the modified Khalfa questionnaire for severity of hyperacusis were compared.
Results: Twenty-two of the 25 patients (88%) reported subjective resolution of their symptoms following treatment. 
Post-treatment audiograms showed significant improvement in average LDL from 81.3 ± 3.2 dB to 86.4 ± 2.6 dB (P < 
.001), indicating increased sound tolerability. The VAS discomfort level also showed significant improvement from a pre-
treatment average of 7.7 ± 1.1 to 3.7 ± 1.6 post-treatment (P < .001). There was also significant improvement in the 
average total score on modified Khalfa questionnaire (32.2 ± 3.6 vs 22.0 ± 5.7, P < .001).
Conclusions: The majority of patients with hyperacusis demonstrated symptomatic improvement from migraine 
prophylaxis therapy, as indicated by self-reported and audiometric measures. Our findings indicate that, for some patients, 
hyperacusis may share a pathophysiologic basis with migraine disorder and may be successfully managed with multimodal 
migraine prophylaxis therapy.
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disease, tinnitus, autism spectrum disorder, depression, post-
traumatic stress disorder, fibromyalgia, complex regional 
pain syndrome, and chronic migraine.6-10 Treatment options 
for hyperacusis include avoidance of provocative stimuli, 
cognitive behavioral therapy, tinnitus retraining therapy, 
hearing amplification, and surgical reinforcement of the 
round and oval windows.11-14 Hyperacusis as it relates to 
chronic migraine is well described and is typically called 
“phonophobia” in the migraine literature. It is a symptom 
commonly found in patients with migraine and is strongly 
associated with the severity of headache.15 While many stud-
ies have focused on the auditory disturbances of migraine 
headache, to our knowledge there have not been any studies 
in which patients presenting for hyperacusis were evaluated 
for migraine. In this cohort, we aimed to describe the rela-
tionship of hyperacusis and migraine in patients presenting 
for the evaluation of hyperacusis and to assess the impact of 
a multi-modal migraine prophylactic regimen on hyperacu-
sis severity.
Methods
In this cohort, we describe patients with hyperacusis who 
were referred to our tertiary care neurotology practice from 
2015 to 2018. Following Institutional Review Board 
approval, patients with the subjective complaint of hyper-
sensitivity to sound were asked to fill out a modified Khalfa 
questionnaire on severity of hyperacusis symptoms. Patients 
with a modified Khalfa score of >28 were considered 
hyperacoustic and those with a score <28 were considered 
normal. Audiograms and imaging of the brain and internal 
auditory canals were obtained to rule out underlying causes. 
Patients were included in the study if their symptoms were 
persistent for a minimum of six months and their average 
loudness discomfort level (LDL) was ≤85 dB.16 By con-
trast, most normal patients have an average LDL between 
86 and 98 dB.16 Average LDL was calculated by averaging 
the LDL at 0.125, 0.25, 0.5, 1, 2, 4, and 8 kHz.17 Patients 
with misophonia or history of only temporary sensitivity to 
sound (e.g., only during episodic migraine headache) were 
excluded from the study.
Twenty-five patients with hyperacusis were included in 
this study and treated with a multi-modal migraine prophy-
lactic regimen. As part of the migraine prophylaxis therapy, 
patients were counseled on implementing lifestyle modifica-
tions. This included dietary modifications, which consisted 
of avoiding foods containing certain preservatives, fermented 
products, chocolate, nuts, eggs, alcohol, fresh breads/yeast 
products, aged/processed meats, certain beans, certain fruit 
(high histamine), and pickled or preserved fruits/vegetables. 
In addition, dietary supplementation with magnesium 400 
mg bid and riboflavin (vitamin B2) 200 mg bid was pre-
scribed. We did not restrict sodium intake as long as the 
patient stayed well-hydrated. Patients were also instructed to 
eat three meals and sleep on a regular schedule on weekends 
and weekdays to avoid fatigue, hunger, and dehydration.18
The patients were also prescribed pharmacologic 
migraine prophylaxis in a step-wise agent- and dose-esca-
lating manner illustrated in Figure 1. The patients were 
most commonly started on nortriptyline 25 mg PO qhs and 
gradually escalated by 25 mg every three weeks to a maxi-
mum dose of 75 mg if symptoms had not improved. 
Nortriptyline was indicated for patients who had difficulty 
sleeping, interrupted sleep, or endorsed significant stress or 
anxiety. Nortriptyline was not used for patients already tak-
ing an antidepressant. If patients had comorbid hyperten-
sion or nortriptyline was contraindicated, verapamil 120 mg 
PO qhs was started and escalated by 60 mg every two weeks 
to a maximum dose of 240 mg if symptoms were not 
improved. Verapamil was not used for patients with systolic 
blood pressure <100 mmHg or heart rate <60 BPM. 
Patients who failed to improve on a single agent were 
started on a second agent (either topiramate or verapamil) 
and dose-escalated to effect, unless contraindicated. If the 
first-line therapy was ineffective or contraindicated, topira-
mate 25 mg PO qhs with weekly escalation of 25 mg up to 
150 mg was prescribed. Patients were instructed to maintain 
the dosage of their current regimen once they achieved sat-
isfactory control of their symptoms.
A modified Khalfa questionnaire was administered to 
assess the severity of hyperacusis in terms of impairment of 
quality of life (QOL).19 The questionnaire was modified 
from the author’s original version by removing the QOL 
domains that did not demonstrate satisfactory internal con-
sistency reliability in the original study. The resulting modi-
fied questionnaire utilized Likert-type scales to assess QOL 
in three domains: attention, emotional, and social. The pos-
sible total score ranged from zero to 42; scores above 28 
indicate hyperacusis and scores below or equal to 28 indi-
cate non-hyperacusis or normal.19 Additionally, we recorded 
a baseline subjective discomfort level using a visual analog 
scale (VAS). Patients were then prescribed multi-modal 
migraine prophylaxis and followed at 3-month intervals. 
All patients were seen at three and six months. A final eval-
uation was performed at the six-month visit. Paired sample 
t-test was performed to compare pre- and post-treatment 
scores. Independent sample t-test was used to compare 
post-treatment improvement in hyperacusis discomfort 
measured by VAS between the sub cohorts. SPSS 17.0 soft-
ware (SPSS Inc., Chicago, IL, USA) was used for statistical 
analysis with a 0.05 alpha considered significant.
Results
The average age of patients was 48.5 ± 12.0 years (range, 
23-71 years). There were 19 female (76%) and 6 male par-
ticipants (24%), female to male ratio 3:1. The prevalence of 
migraine-related symptoms are shown in Table 1. At the 
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time of the final visit, 15 patients (60%) were on a single 
agent, nine patients (36%) were on two agents, and one 
patient (4%) was on three agents (Table 2). Post-treatment 
testing showed significant improvement in average loudness 
discomfort level (LDL) from 81.3 ± 3.2 dB to 86.4 ± 2.6 
dB (P < .001), indicating increased sound tolerability. A 
total of 22 patients (88%) reported subjective resolution of 
their symptoms after treatment.
As shown in Figure 2, there was significant improve-
ment between pre- and post-treatment scores in all three 
Figure 1. Algorithm for step-wise migraine prophylactic regimen.
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domains of the Khalfa questionnaire: emotional domain 
(9.5 ± 1.4 vs 6.5 ± 2.2, P < .001), social domain (13.1 ± 
1.6 vs 9.5 ± 2.3, P < .001), and attention domain (9.6 ± 
1.3 vs 5.9 ± 2.1, P < .001). Additionally, the average total 
Khalfa score improved significantly from 32.2 ± 3.6 pre-
treatment to 22.0 ± 5.7 post-treatment (P < .001), indicat-
ing improvement to non-hyperacusis. The VAS subjective 
discomfort level also showed significant improvement 
from a pre-treatment average of 7.7 ± 1.1 to 3.7 ± 1.6 
post-treatment (P < .001). Post-treatment improvement in 
VAS discomfort level for patients with and without a his-
tory of migraine (4.1 ± 2.2 vs 3.9 ± 2.1, P = .822), those 
with and without tinnitus (4.5 ± 1.2 vs 2.9 ± 2.5, P = 
.040), and those whose headache frequency did and did 
not improve as defined by at least 50% decrease in head-
ache frequency (4.2 ± 1.1 vs 2.8 ± 2.1, P = .066) are 
shown in Table 3.
Discussion
We found a significant history of migraine-related symp-
toms among patients presenting for evaluation of hyperacu-
sis (Table 1). The majority of our patients with hyperacusis 
showed significant improvement in QOL, subjective reso-
lution of their symptoms, and improved audiometric results 
following treatment with our multi-modal migraine prophy-
lactic regimen. The average pre-treatment score on the 
modified Khalfa questionnaire showed hyperacoustic status 
which significantly improved to an average score well 
below the threshold post-treatment.
Various treatments for hyperacusis have been described; 
however, more randomized controlled trials are needed to 
evaluate the efficacy of these treatment modalities.20 In 
2016, Silverstein et al. described minimally invasive sur-
gical reinforcement of the round and oval windows with 
temporalis fascia or tragal perichondrium in a series of six 
patients. The authors cautioned that the test-retest reliabil-
ity of the LDL measurement can depend on the consis-
tency of instructions provided by the tester, however other 
studies have reported that the LDL was a reliable tool for 
follow-up.12 Recently, sound therapy has been used to 
improve the LDL of patients with tinnitus and co-morbid 
hyperacusis and recent reviews have confirmed modest 
benefit.11,21 The present study is the first to describe treat-
ment of hyperacusis with a multi-modal migraine prophy-
lactic regimen. It is the experience of our practice that 
migraine prophylaxis generally yields better results than 
sound generators, and that all patients presenting for treat-
ment of persistent hyperacusis should be offered a trial of 
migraine prophylaxis along with lifestyle and dietary 
modifications as first-line therapy.
The selected dosages of nortriptyline, verapamil, and 
topiramate have previously been shown to be both safe and 
effective for treatment of other otologic conditions.22-25 
However, side effects are a possibility and patients should 
be counseled and monitored accordingly. Nortriptyline 
most commonly can cause lightheadedness, dizziness, and 
sedation, and baseline EKG with QTc monitoring is a con-
sideration. Verapamil can also cause lightheadedness and 
dizziness as well as constipation. Topiramate can cause 
mild tingling in the extremities, mild appetite suppression, 
and mild taste disturbance. Our most commonly reported 
side effect was hypotension while on verapamil due to indi-
viduals beginning concomitant anti-hypertensive use; these 
Table 1. Prevalence of Migraine-Related Symptoms and Family 
History of Migraine-Related Disorders in the Cohort.
Clinical Feature
No. of 
Patients
Proportion 
of the 
Cohort
Previous history of
 Visual motion sensitivity 18 72%
 Light sensitivity 19 76%
 Head motion sensitivity 14 56%
 Odor sensitivity 13 52%
 Weather change sensitivity 8 32%
 Motion sickness 18 72%
 Mental confusion (head/brain fog) 20 80%
 Previous medication for migraine 10 40%
 Sinus pain, facial pressure, or 
headache when exposed to wind or 
air conditioner
18 72%
 Scalp or face allodynia 5 20%
 Ice cream headache (brain freeze) 15 60%
 Sinus headache 18 72%
 Unilateral neck stiffness 18 72%
 Tinnitus 16 64%
 Daily headache 5 20%
 Frequent headache (≥one per week) 20 80%
 Sleep problems 7 28%
Family history of
 Migraine headache 4 16%
 Meniere’s disease 1 4%
 Motion sickness 1 4%
Table 2. Eventual Medication Regimen at the Six-Month 
Follow-Up Visit.
Medication
No. of 
Patients
Proportion of 
the Cohort Using 
Medication
Nortriptyline 7 28%
Verapamil 6 24%
Topiramate 2 8%
Nortriptyline + Verapamil 5 20%
Nortriptyline + Topiramate 4 16%
Nortriptyline + Verapamil 
+ Topiramate
1 4%
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individuals were switched to topiramate only or to nortrip-
tyline and topiramate (Table 2).
While the mechanisms underlying hyperacusis remain 
unknown, it is theorized that different types of hyperacusis 
may have distinct pathophysiological mechanisms.6,8,13 For 
example, the evidence has supported the phenomenon of 
“excessive central gain enhancement” as the etiological fac-
tor in loudness hyperacusis and tinnitus. The central gain 
model posits that tinnitus and hyperacusis result from a 
compensatory increase in gain or neural amplification in the 
central auditory system to compensate for a loss of sensory 
input from the cochlea.26,27 Hyperacusis associated with 
chronic pain has been theorized to be caused by abnormal 
activity in the thalamus, locus coeruleus, and other conver-
gent sites in the brainstem.28
A hallmark of migraine pathophysiology is altered per-
ception of normal sensory stimuli such as sound, light, 
smell, and touch.29,30 Central sensitization is the process 
by which trigeminal and cervical nociceptors become 
especially sensitive to normal stimuli leading to allodynia 
and migraine.31,32 It is believed that in migraine, like in 
other chronic pain conditions, a sensitization of periph-
eral and nociceptive pathways can spread to higher 
central circuits and compromise auditory modulation 
mechanisms, leading to hyperacusis. In fact, the sites of 
convergence of both migraine and chronic pain syn-
dromes are in the locus coeruleus and its ascending pro-
jections to the thalamus. Convergence of these sensory 
pathways results in symptom amplification such that 
light, for example, can cause increased firing in the tri-
geminal sensory fibers.28 When this sensitization occurs 
specifically for sound, hyperacusis may be the expected 
result, particularly in patients with migraine and migraine-
related otologic disorders like vestibular migraine and 
Meniere’s disease.18,23
The interrelation of the migraine and chronic pain path-
ways may also shed light on the types of hyperacusis that are 
best targeted by the migraine treatments explored in this 
paper. It is likely that, of the various types of hyperacusis 
including loudness, annoyance, fear, and pain, migraine 
Figure 2. Pre- and post-treatment average scores on different domains of modified Khalfa questionnaire.
Table 3. Comparison of Average Post-Treatment Improvement 
in Hyperacusis Discomfort Measured by a Visual Analog Scale.
Clinical Feature 
Present?  
 Yes No P value
History of migraine 4.1 ± 2.2 3.9 ± 2.1 .822
Tinnitus 4.5 ± 1.2 2.9 ± 2.5 .040
*Improvement 
in headache 
frequency
4.2 ± 1.1 2.8 ± 2.1 .066
*Improvement defined by ≥50% decrease in headache frequency.
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prophylactic treatment will best target loudness and pain 
hyperacusis. Loudness and pain hyperacusis have the closest 
relation with alterations in the threshold of hearing. By 
effectively lowering the threshold for firing of sensory neu-
rons, migraine can increase the perceived noise level of spe-
cific sounds.8 Furthermore, via the convergence of migraine 
and pain pathways, this altered sensitivity to sound can 
transform into a perception of pain as well. By helping treat 
migraine and the subsequent changes in hearing threshold, 
these medications should reduce both the perceived loud-
ness of sound and any pain associated with it. It is possible 
that annoyance and fear hyperacusis, which are defined 
more so by their mood disturbances, would be improved by 
these medications (particularly nortriptyline) as well, how-
ever further studies are needed to elucidate the efficacy of 
migraine treatments for different types of hyperacusis.
Interestingly, many parallels exist between hyperacusis 
and tinnitus, which may explain the significance in post-
treatment improvement of VAS discomfort level in patients 
with concurrent tinnitus compared to those without tinni-
tus (Table 3). Similar to hyperacusis, the neural pathways 
involved in tinnitus also overlap with mood and pain dis-
orders.33-35 Additionally, tinnitus shares a strong associa-
tion with migraine.36 It is not surprising then that these 
medications can reduce the perception of both hyperacusis 
and tinnitus, likely by acting on the same root cause or 
shared neural pathways.
The main limitation of this study was the lack of a control 
group. Although patients were only included if their symp-
toms had persisted for six months, we cannot say with cer-
tainty that the improvements shown were solely due to our 
treatments because of the possibility of placebo effect. 
However, the long duration of symptoms prior to presenta-
tion and a response rate of 88% is suggestive of a treatment 
effect. Another limitation is the inherently subjective nature 
of the outcome measures of hyperacusis. The VAS, QOL sur-
vey, and even audiometric LDL testing are patient-reported 
scores and vulnerable to response bias. Additionally, the 
dietary and lifestyle modifications required for migraine pro-
phylaxis are rigorous. The variability in adherence to our pre-
scribed regimen was not quantified. Our evidence suggests 
our approach may be efficacious for certain types of hyper-
acusis but may not be effective for all subtypes. For example, 
we did not have any subjects with hearing loss in our study 
cohort and so could not investigate the difference in treat-
ment efficacy for patients with hearing loss and tinnitus ver-
sus those with normal hearing and no tinnitus. A larger study 
will be needed to adequately evaluate the treatment effect in 
all subtypes of hyperacusis. Finally, due to limited study 
duration we are unable to assess the long-term efficacy of our 
treatment. Future studies will require the addition of a pla-
cebo control group, and the development of a valid objective 
measure of hyperacusis to demonstrate efficacy.
Conclusion
The majority of patients with hyperacusis demonstrated 
symptomatic improvement from migraine prophylaxis ther-
apy, as indicated by self-reported and audiometric measures. 
Our findings indicate that, for some patients, hyperacusis 
may share a pathophysiologic basis with migraine disorder 
and may be successfully managed with multimodal migraine 
prophylaxis therapy.
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